Hungary Pharmaceuticals & Healthcare Report

Published 05 May 2015

  • 110 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
Hungary Pharmaceuticals & Healthcare Report

BMI View: Hungary's attractiveness to multinational drugmakers will be impeded by onerous regulatory burden, pricing pressures and punitive taxes on pharmaceutical companies. Combined, these factors will impede growth in phar maceutical sales over the short- term. Consumer demand for over-the-counter medicines and greater uptake of generic medicines will be the primary drivers of pharmaceutical sales growth, as uptake of innovative drugs will remain hindered by the pricing sensitivity and budgetary constraints of the OEP national healthcare fund .

Headline Expenditure Projections

  • Pharmaceuticals: HUF618.0bn (USD2.66bn) in 2014 to HUF624.09bn (USD2.30bn) in 2015; +1.0% in local currency terms and -13.2% in US dollar terms.

  • Healthcare: HUF2,366.20bn (USD10.17bn) in 2014 to HUF2,411.07bn (USD8.90bn) in 2015; +1.9% in local currency terms and -12.4% in US dollar terms.

Risk/Reward Index

Our proprietary Risk/Reward assessment tool has been gradually adjusted to be increasingly transparent and sensitive in relation to potential Rewards. Therefore, as Hungary's market opportunity has worsened, it has slipped down our regional table. Hungary currently ranks ninth out of the 20 regional markets profiled in the Central and Eastern Europe region, with a score of 51.2. While its Risks profile is generally predictable, Hungary's Rewards score continues to reflect its challenging pharmaceutical market outlook.

Key Trends & Developments

  • In April 2015, Hungary's Association of Health Technology Suppliers and Medical Device Manufacturers (ETOSZ) and the Association of Medical Device Manufacturers (OSZ) called a crisis meeting to discuss hospital debt issues. The associations claimed that hospitals owed, with interest, more than HUF90bn (USD322mn) to their member companies at the end of March 2015, while the government had announced to allocate only HUF60bn (USD215mn) to service the debt.

  • In March 2015, Judit Bidlo, the head of the reimbursement department of the...

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Operational Risk
14
Industry Forecast
16
Pharmaceutical Market Forecast
16
Table: Pharmaceutical Sales, Historical Data And Forecasts (Hungary 2011-2019)
17
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Hungary 2011-2019)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Hungary 2011-2019)
20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Hungary 2011-2019)
20
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Hungary 2011-2019)
22
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Hungary 2011-2019)
24
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Hungary 2011-2019)
26
OTC Medicine Market Forecast
26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Hungary 2011-2019)
28
Pharmaceutical Trade Forecast
28
Table: Top 10 Export Partners For Pharmaceuticals
30
Table: Pharmaceutical Trade Data And Forecasts (Hungary 2013-2019)
31
Table: Pharmaceutical Trade Data And Forecasts local currency (Hungary 2013-2019)
31
Key Risks To BMI's Forecast Scenario
31
Macroeconomic Forecasts
33
Economic Analysis
33
Table: GDP By Expenditure (Hungary 2012-2019)
40
Industry Risk Reward Ratings
41
Central And Eastern Europe Risk/Reward Index
41
Hungary Risk/Reward Index
47
Rewards
47
Risks
47
Market Overview
49
Industry Trends And Developments
51
Epidemiology
51
Healthcare System
54
Table: Healthcare Resources (Hungary 2009-2014)
55
Table: Healthcare Personnel (Hungary 2009-2014)
55
Table: Healthcare Activity (Hungary 2009-2014)
56
Healthcare Funding
56
Research and Development (R&D)
57
Clinical Trials
57
Regulatory Development
60
Pharmaceutical Advertising
61
Intellectual Property Regime
62
Pricing Regime
63
Table: OEP Reimbursement Changes, September 2014
65
Pharmaceutical Mark-Ups
65
Table: Hungary - Pharmaceutical Price Build-Up (%)
66
Reimbursement Regime
66
Competitive Landscape
69
Company Profile
74
Gedeon Richter
74
Egis Pharmaceuticals (Servier)
79
Pfizer
83
Novartis
85
Sanofi
87
GlaxoSmithKline
89
Merck & Co
91
Eli Lilly
93
Teva
95
Demographic Forecast
98
Table: Population Headline Indicators (Hungary 1990-2025)
99
Table: Key Population Ratios (Hungary 1990-2025)
99
Table: Urban/Rural Population And Life Expectancy (Hungary 1990-2025)
100
Table: Population By Age Group (Hungary 1990-2025)
100
Table: Population By Age Group % (Hungary 1990-2025)
101
Glossary
103
Methodology
105
Pharmaceutical Expenditure Forecast Model
105
Healthcare Expenditure Forecast Model
105
Notes On Methodology
106
Risk/Reward Index Methodology
107
Index Overview
108
Table: Pharmaceutical Risk/Reward Index Indicators
108
Indicator Weightings
109

The Hungary Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Hungary Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Hungary pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Hungary, to test other views - a key input for successful budgeting and strategic business planning in the Hungarian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Hungarian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Hungary.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%